Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World study confirms Mogamulizumab's effectiveness against rare skin cancer

NCT ID NCT06113081

Disease control Sponsor: Fondazione Italiana Linfomi - ETS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 100 adults with cutaneous T-cell lymphoma (a rare type of skin cancer) who had already tried at least one other treatment. Researchers wanted to see how well the drug mogamulizumab works in everyday medical practice, not just in controlled trials. They measured how many patients had their cancer shrink or disappear for at least 4 months. The goal is to understand the drug's real-world benefits and safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

100 people

The number who actually took part.

Started

Jun 2024

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients affected by relapsed/refractory Cutaneous T-cell Lymphoma who have received Mogamulizumab in real life settings

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed diagnosis of CTCL according to the EORTC 2017 update criteria (Trautinger et al, Eur J Cancer, 2017) * Age ≥18 years * Have failed at least one previous line of systemic therapy * Have received mogamulizumab in real life setting after the approval and reimbursement of the drug from the National Health System in December 2020 * Have received first dose of mogamulizumab between 01/01/2021 and 31/01/2023 * Have received mogamulizumab at the standard approved dose (1.0 mg/kg intravenously on days 1, 8, 15 and 22 of the first cycle and on days 1 and 15 of subsequent cycles) * Availability of complete medical records. Exclusion Criteria: • Patients not meeting the above-mentioned inclusion criteria

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cutaneous T-cell lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

mycosis fungoides primary cutaneous T-cell non-Hodgkin lymphoma Recurrence Sezary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cutaneous T-cell lymphoma Cutaneous T-cell lymphoma/mycosis fungoides Cutaneous T-cell lymphoma/sezary syndrome

Contacts and locations

Locations

  • Clinica Dermatologia - A.O.U. Policlinico Consorziale

    Bari, Italy

  • Clinica Dermatologica - A.O.U. Luigi Vanvitelli

    Naples, Italy

  • Clinica di Ematologia - AOU Ospedali Riuniti delle Marche

    Ancona, Italy

  • Divisione di Ematologia - IRCCS Policlinico San Matteo

    Pavia, Italy

  • Istituto di Ematologia - Policlinico S.Orsola-Malpighi

    Bologna, Italy

  • S.C. Dermatologia - IRCCS Policlinico S. Martino

    Genova, Italy

  • S.C. Dermatologia U - A.O.U. Città della Salute e della Scienza di Torino

    Torino, Italy

  • S.C. Ematologia - ASST Spedali Civili

    Brescia, Italy

  • S.C. Ematologia e CTMO - A.O. Brotzu Ospedale Businco

    Cagliari, Italy

  • S.C. Ematologia e Terapie Cellulari - IRCCS Policlinico S. Martino

    Genova, Italy

  • S.C. Ematologia e Trapianto emopoietico - A.O. S.Giuseppe Moscati

    Avellino, Italy

  • U.O. Ematologia - Ospedale Guglielmo da Saliceto

    Piacenza, Italy

  • U.O.C. Dermatologia - Ospedale Maggiore Policlinico Fondazione IRCCS Ca' Granda

    Milan, Italy

  • U.O.C. Dermatologia . A.O.U. di Padova

    Padova, Italy

  • U.O.C. Ematologia - A.O.U. Senese

    Siena, Italy

  • U.O.C. Ematologia - IRCCS Istituto Tumori Giovanni Paolo II

    Bari, Italy

  • U.O.C. Ematologia - Policlinico Tor Vergata

    Roma, Italy

  • U.O.C. di Ematologia - A.O.U. Policlinico S. Marco

    Catania, Italy

  • UOSD Porfirie e Malattie Rare - IRCCS I.F.O. San Gallicano

    Roma, Italy

  • Unità funzionale di Ematologia - Azienda Ospedaliera Universitaria Careggi

    Florence, Italy

  • Verona - AOU Integrata di Verona - U.O. Ematologia

    Verona, 37134, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.